0.1632USD-3.43%Mkt Cap: 7.32M USDP/E: —Last update: 2026-05-26
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phas…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap7.32M USD
Enterprise Value10.57M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.21M USD
Revenue/Share—
Last Price0.1632 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.68
EPS (TTM)-0.25
EPS (Forward)—
52W Range
0.13200% of range33.66
52W High33.66 USD
52W Low0.1320 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE103.99%
ROA-1990.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.96M USD
CapEx (TTM)13.11K USD
FCF Margin—
FCF Yield—
Net Debt-465.17K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.15
Current Ratio0.96
Quick Ratio0.66
Book Value/Sh-0.3630 USD
Cash/Share0.0430 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.88M
Float29.07M
Insiders38.53%
Institutions3.29%
Short Interest
Short Ratio0.1d
Short % Float3.33%
Short % Out.2.41%
Shares Short1.08M
Short (prev mo.)705.23K
Technical
SMA 500.2008 (-18.7%)
SMA 2001.097 (-85.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)18.31M
Avg Vol (10d)35.74M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—